EssilorLuxottica Société anonyme (EL.PA)
EUR 257.5
(1.9%)
EUR 257.5
(1.9%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 12.65 Billion EUR | 4.09% |
| 2022 | 12.33 Billion EUR | 27.03% |
| 2021 | 9.71 Billion EUR | 24.9% |
| 2020 | 7.77 Billion EUR | -11.01% |
| 2019 | 8.73 Billion EUR | 63.2% |
| 2018 | 5.35 Billion EUR | 18.46% |
| 2017 | 4.51 Billion EUR | 52.57% |
| 2016 | 2.96 Billion EUR | 4.41% |
| 2015 | 2.83 Billion EUR | 34.77% |
| 2014 | 2.1 Billion EUR | 6.05% |
| 2013 | 1.98 Billion EUR | 2.21% |
| 2012 | 1.94 Billion EUR | 20.2% |
| 2011 | 1.61 Billion EUR | 7.48% |
| 2010 | 1.5 Billion EUR | 18.85% |
| 2009 | 1.26 Billion EUR | 2.74% |
| 2008 | 1.23 Billion EUR | 5.55% |
| 2007 | 1.16 Billion EUR | 5.89% |
| 2006 | 1.1 Billion EUR | 12.21% |
| 2005 | 981.55 Million EUR | 2.37% |
| 2004 | 958.83 Million EUR | 4.52% |
| 2003 | 917.39 Million EUR | -1.98% |
| 2002 | 935.93 Million EUR | 8.45% |
| 2001 | 862.99 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 6.46 Billion EUR | 0.0% |
| 2023 Q2 | 6.34 Billion EUR | 0.0% |
| 2023 Q4 | 6.44 Billion EUR | 0.0% |
| 2023 FY | 12.84 Billion EUR | 4.09% |
| 2022 Q4 | 6.4 Billion EUR | 0.0% |
| 2022 FY | 12.33 Billion EUR | 27.03% |
| 2022 Q2 | 5.93 Billion EUR | 0.0% |
| 2021 Q2 | 4.07 Billion EUR | 0.0% |
| 2021 Q4 | 5.69 Billion EUR | 0.0% |
| 2021 FY | 9.71 Billion EUR | 24.9% |
| 2020 Q4 | 3.99 Billion EUR | 0.0% |
| 2020 Q2 | 3.78 Billion EUR | 0.0% |
| 2020 FY | 7.77 Billion EUR | -11.01% |
| 2019 Q4 | 4.37 Billion EUR | 0.0% |
| 2019 Q2 | 4.36 Billion EUR | 0.0% |
| 2019 FY | 8.73 Billion EUR | 63.2% |
| 2018 Q4 | 3.21 Billion EUR | 0.0% |
| 2018 FY | 5.35 Billion EUR | 18.46% |
| 2018 Q2 | 2.13 Billion EUR | 0.0% |
| 2017 FY | 4.51 Billion EUR | 52.57% |
| 2017 Q2 | 1.66 Billion EUR | 0.0% |
| 2017 Q4 | 2.85 Billion EUR | 0.0% |
| 2016 FY | 2.96 Billion EUR | 4.41% |
| 2016 Q2 | 1.49 Billion EUR | 0.0% |
| 2016 Q4 | 1.46 Billion EUR | 0.0% |
| 2015 Q2 | 1.42 Billion EUR | 0.0% |
| 2015 FY | 2.83 Billion EUR | 34.77% |
| 2015 Q4 | 1.4 Billion EUR | 0.0% |
| 2014 Q2 | 764 Million EUR | 0.0% |
| 2014 FY | 2.1 Billion EUR | 6.05% |
| 2014 Q4 | 1.34 Billion EUR | 0.0% |
| 2013 Q2 | 1 Billion EUR | 0.0% |
| 2013 FY | 1.98 Billion EUR | 2.21% |
| 2013 Q4 | 985 Million EUR | 0.0% |
| 2012 Q4 | 604.31 Million EUR | 0.0% |
| 2012 Q2 | 604.31 Million EUR | 0.0% |
| 2012 Q1 | 604.31 Million EUR | 16.14% |
| 2012 FY | 1.94 Billion EUR | 20.2% |
| 2012 Q3 | 604.31 Million EUR | 0.0% |
| 2011 Q2 | 520.34 Million EUR | 0.0% |
| 2011 Q3 | 520.34 Million EUR | 0.0% |
| 2011 Q4 | 520.34 Million EUR | 0.0% |
| 2011 FY | 1.61 Billion EUR | 7.48% |
| 2011 Q1 | 520.34 Million EUR | 10.96% |
| 2010 Q3 | 468.94 Million EUR | 0.0% |
| 2010 FY | 1.5 Billion EUR | 18.85% |
| 2010 Q4 | 468.94 Million EUR | 0.0% |
| 2010 Q2 | 468.94 Million EUR | 0.0% |
| 2010 Q1 | 468.94 Million EUR | 18.48% |
| 2009 Q1 | 395.79 Million EUR | 4.29% |
| 2009 Q2 | 395.79 Million EUR | 0.0% |
| 2009 Q3 | 395.79 Million EUR | 0.0% |
| 2009 Q4 | 395.79 Million EUR | 0.0% |
| 2009 FY | 1.26 Billion EUR | 2.74% |
| 2008 Q3 | 379.52 Million EUR | 0.0% |
| 2008 Q2 | 379.52 Million EUR | 0.0% |
| 2008 Q1 | 379.52 Million EUR | 4.27% |
| 2008 FY | 1.23 Billion EUR | 5.55% |
| 2008 Q4 | 379.52 Million EUR | 0.0% |
| 2007 FY | 1.16 Billion EUR | 5.89% |
| 2007 Q4 | 363.96 Million EUR | 0.0% |
| 2007 Q3 | 363.96 Million EUR | 0.0% |
| 2007 Q2 | 363.96 Million EUR | 0.0% |
| 2007 Q1 | 363.96 Million EUR | 7.3% |
| 2006 Q1 | 339.2 Million EUR | 14.26% |
| 2006 Q4 | 339.2 Million EUR | 0.0% |
| 2006 Q3 | 339.2 Million EUR | 0.0% |
| 2006 Q2 | 339.2 Million EUR | 0.0% |
| 2006 FY | 1.1 Billion EUR | 12.21% |
| 2005 Q4 | 296.86 Million EUR | 0.0% |
| 2005 Q2 | 296.86 Million EUR | 0.0% |
| 2005 FY | 981.55 Million EUR | 2.37% |
| 2005 Q1 | 296.86 Million EUR | 18808.81% |
| 2005 Q3 | 296.86 Million EUR | 0.0% |
| 2004 FY | 958.83 Million EUR | 4.52% |
| 2004 Q3 | -1.58 Million EUR | 0.0% |
| 2004 Q1 | -1.58 Million EUR | 57.58% |
| 2004 Q2 | -1.58 Million EUR | 0.0% |
| 2004 Q4 | -1.58 Million EUR | 0.0% |
| 2003 Q1 | -3.74 Million EUR | 42.86% |
| 2003 Q4 | -3.74 Million EUR | 0.0% |
| 2003 FY | 917.39 Million EUR | -1.98% |
| 2003 Q3 | -3.74 Million EUR | 0.0% |
| 2003 Q2 | -3.74 Million EUR | 0.0% |
| 2002 Q3 | -6.54 Million EUR | 0.0% |
| 2002 FY | 935.93 Million EUR | 8.45% |
| 2002 Q2 | -6.54 Million EUR | 0.0% |
| 2002 Q1 | -6.54 Million EUR | 9.74% |
| 2002 Q4 | -6.54 Million EUR | 0.0% |
| 2001 FY | 862.99 Million EUR | 0.0% |
| 2001 Q3 | -7.25 Million EUR | 0.0% |
| 2001 Q2 | -7.25 Million EUR | 0.0% |
| 2001 Q1 | -7.25 Million EUR | 0.0% |
| 2001 Q4 | -7.25 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Crossject Société Anonyme | 5.66 Million EUR | -223342.189% |
| Safe Orthopaedics SA | 10.7 Million EUR | -118143.811% |
| Spineway SA | 6.06 Million EUR | -208502.505% |
| Amplitude Surgical SA | 23.96 Million EUR | -52723.102% |
| Sartorius Stedim Biotech S.A. | 749 Million EUR | -1589.987% |
| bonyf N.V. | 66.3 Thousand EUR | -19089602.6% |